AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14665549 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micro g kg(‐1) h(‐1) + Propofol 3 mg kg(‐1) h(‐1)
Number of subjects: 27
Study 14665549 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 27
Study 14665549 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertex‐inion electrode site
Number of subjects: 27
Study 14665549 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertex‐inion electrode site after 30 min of propofol infusion
Number of subjects: 27
Study 14665549 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertex‐mastoid electrodes
Number of subjects: 27
Study 11240946 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fluticasone propionate (FP) 88 microg (2 puffs of 44 microg) twice daily
Number of subjects: 533
Study 9252847 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg octreotide intramuscularly
Number of subjects: 16
Study 9252847 — intervention group
Group type: COMPARATOR
Intervention: Secretin stimulation (1 IU/kg intravenous bolus)
Number of subjects: 16
Study 8238130 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (ampicillin‐amoxicillin and erythromycin)
Number of subjects: 277
Study 8238130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 3120568 — intervention group
Group type: EXPERIMENTAL
Intervention: High nitrogen diet (366 mg N/(kg.d))
Number of subjects: 9
Study 3120568 — intervention group
Group type: COMPARATOR
Intervention: Low nitrogen diet (191 mg N/(kg.d))
Number of subjects: 9
Study 3120568 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 9
Study 30453553 — intervention group
Group type: EXPERIMENTAL
Intervention: MICRO (5-min microbouts of activity for 9 hours)
Number of subjects: 22
Study 30453553 — intervention group
Group type: EXPERIMENTAL
Intervention: ONE (45-min continuous physical activity)
Number of subjects: 22
Study 30453553 — intervention group
Group type: COMPARATOR
Intervention: SED (sedentary control condition)
Number of subjects: 22
Study 27082782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth breast shields
Number of subjects: 101
Study 27082782 — intervention group
Group type: COMPARATOR
Intervention: No breast shielding (Control)
Number of subjects: 101
Study 24989946 — intervention group
Group type: EXPERIMENTAL
Intervention: Abediterol 5 µg
Number of subjects: 48
Study 24989946 — intervention group
Group type: EXPERIMENTAL
Intervention: Abediterol 10 µg
Number of subjects: 48
Study 24989946 — intervention group
Group type: EXPERIMENTAL
Intervention: Abediterol 25 µg
Number of subjects: 48
Study 24989946 — intervention group
Group type: EXPERIMENTAL
Intervention: Abediterol 50 µg
Number of subjects: 48
Study 24989946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22156609 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC)
Number of subjects: 158
Study 22156609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 158
Study 20237219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic clinical trials, methodological guidance, and coverage with evidence development
Number of subjects: 0
Study 18485420 — intervention group
Group type: EXPERIMENTAL
Intervention: New test of executive function (selection between stimulus-oriented and stimulus-independent thought)
Number of subjects: 15
Study 18485420 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical test of executive function (random response generation)
Number of subjects: 15
Study 18485420 — intervention group
Group type: EXPERIMENTAL
Intervention: New test of executive function
Number of subjects: 15
Study 18485420 — intervention group
Group type: COMPARATOR
Intervention: Classical test of executive function
Number of subjects: 15
Study 15975472 — intervention group
Group type: EXPERIMENTAL
Intervention: Advantec Legacy 20000 with NeoSoniX
Number of subjects: 410
Study 15975472 — intervention group
Group type: COMPARATOR
Intervention: Standard Legacy 20000
Number of subjects: 410
Study 15975472 — intervention group
Group type: COMPARATOR
Intervention: Advantec Legacy 20000
Number of subjects: 410
Study 12621276 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy (AAT) for 15 minutes
Number of subjects: 35
Study 12621276 — intervention group
Group type: COMPARATOR
Intervention: Standard condition (15 minutes with magazines)
Number of subjects: 35
Study 10502454 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycose (carbohydrate)
Number of subjects: 0
Study 10502454 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal (equal calories)
Number of subjects: 0
Study 10502454 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study 7554338 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical salbutamol
Number of subjects: 37
Study 7554338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 1961960 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol as single induction and maintenance hypnotic (group II)
Number of subjects: 20
Study 1961960 — intervention group
Group type: COMPARATOR
Intervention: Thiopental for intravenous induction with oxygen/nitrous oxide (30/70%) for maintenance (group I)
Number of subjects: 20
Study 7013978 — intervention group
Group type: COMPARATOR
Intervention: BCNU or methyl-CCNU chemotherapy without radiotherapy (Category A)
Number of subjects: 115
Study 7013978 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain radiation treatment (6000 rad) with surgery (Category B)
Number of subjects: 115
Study 7013978 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl-CCNU with irradiation
Number of subjects: 115
Study 30165487 — intervention group
Group type: EXPERIMENTAL
Intervention: Single internal thoracic artery (SITA)
Number of subjects: 905
Study 30165487 — intervention group
Group type: COMPARATOR
Intervention: Bilateral internal thoracic artery (BITA)
Number of subjects: 905
Study 30165487 — intervention group
Group type: EXPERIMENTAL
Intervention: SITA
Number of subjects: 905
Study 30165487 — intervention group
Group type: COMPARATOR
Intervention: BITA
Number of subjects: 905
Study 27723134 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamiol® gel once daily as needed (PRN Group)
Number of subjects: 0
Study 27723134 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamiol® gel once daily every day (Continuous group)
Number of subjects: 0
Study 27723134 — intervention group
Group type: COMPARATOR
Intervention: Xamiol® gel twice weekly (Weekend group)
Number of subjects: 0
Study 25396266 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily
Number of subjects: 147
Study 25396266 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 147
Study 24117666 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (200 mg daily)
Number of subjects: 109
Study 24117666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 24117666 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapy (mailed letters emphasizing harmful effects of alcohol)
Number of subjects: 109
Study 22898064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet bee venom pharmacopuncture (SBVP)
Number of subjects: 11
Study 19950569 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp) with NPH
Number of subjects: 220
Study 19950569 — intervention group
Group type: COMPARATOR
Intervention: Human Insulin (HI) with NPH
Number of subjects: 220
Study 17224915 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 0
Study 17224915 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study 17224915 — intervention group
Group type: COMPARATOR
Intervention: NRT and placebo
Number of subjects: 0
Study 15548392 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal and transvaginal ultrasonography
Number of subjects: 121
Study 15548392 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasonography with magnification
Number of subjects: 121
Study 15548392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation
Number of subjects: 121
Study 11577304 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNA with suction
Number of subjects: 43
Study 11577304 — intervention group
Group type: COMPARATOR
Intervention: EUS-FNA without suction
Number of subjects: 43
Study 11577304 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration from the edge of the lymph node
Number of subjects: 43
Study 11577304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytospin-cellblock methods
Number of subjects: 43
Study 9632001 — intervention group
Group type: EXPERIMENTAL
Intervention: DAB389IL-2 (5, 10, or 15 microg/kg daily intravenously for 3 consecutive days each week for 4 weeks)
Number of subjects: 41
Study 9632001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9632001 — intervention group
Group type: EXPERIMENTAL
Intervention: DAB389IL-2
Number of subjects: 41
Study 7891305 — intervention group
Group type: EXPERIMENTAL
Intervention: Itazigrel 5-100 mg (low-dose study)
Number of subjects: 0
Study 7891305 — intervention group
Group type: EXPERIMENTAL
Intervention: Itazigrel 100-600 mg (high-dose study)
Number of subjects: 0
Study 7891305 — intervention group
Group type: EXPERIMENTAL
Intervention: Itazigrel
Number of subjects: 0
Study 3146890 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprotiline
Number of subjects: 71
Study 3146890 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 71
Study 3146890 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover phase with oxaprotiline
Number of subjects: 71
Study 3146890 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover phase with fluvoxamine
Number of subjects: 71
Study 3146890 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response
Number of subjects: 71
Study 3146890 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover phase overall response
Number of subjects: 71
Study 2257065 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA2 synthesis inhibitor, anisodamine
Number of subjects: 42
Study 2257065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 42
Study 9919 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy (N=50)
Number of subjects: 100
Study 9919 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychotherapy (N=50)
Number of subjects: 100
Study 9919 — intervention group
Group type: COMPARATOR
Intervention: Both group and individual psychotherapy
Number of subjects: 100
Study 30771243 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal insert
Number of subjects: 283
Study 30771243 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 283
Study 27914241 — intervention group
Group type: EXPERIMENTAL
Intervention: Trebananib plus pegylated liposomal doxorubicin (PLD) 50 mg/m2 once every 4 weeks plus weekly intravenous trebananib 15 mg/kg
Number of subjects: 223
Study 27914241 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pegylated liposomal doxorubicin (PLD) 50 mg/m2 once every 4 weeks
Number of subjects: 223
Study 25781977 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen annually for 24 months (S1)
Number of subjects: 104
Study 25781977 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose (800 mg albendazole) annually for 24 months (H1)
Number of subjects: 104
Study 25781977 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose (300 mg DEC) with increased frequency (6 monthly) (S2)
Number of subjects: 104
Study 25781977 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose (800 mg albendazole) with increased frequency (H2)
Number of subjects: 104
Study 23429871 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial arrival at high altitude (days 2-4)
Number of subjects: 12
Study 23429871 — intervention group
Group type: EXPERIMENTAL
Intervention: Days 12-15 at high altitude
Number of subjects: 12
Study 21155776 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session manualized TF-CBT
Number of subjects: 64
Study 21155776 — intervention group
Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 64
Study 20095375 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b, 3 million IU, administered rectally on chemotherapy days (twice weekly) for 4 months or more
Number of subjects: 70
Study 20095375 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunomodulator)
Number of subjects: 70
Study 17119538 — intervention group
Group type: EXPERIMENTAL
Intervention: Farampator (500 mg)
Number of subjects: 16
Study 17119538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15292668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCA)
Number of subjects: 209
Study 15292668 — intervention group
Group type: COMPARATOR
Intervention: Other antidepressants
Number of subjects: 209
Study 11698326 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine/propofol (2.5 mg.kg(‐1)*hr(‐1) S(+)‐ketamine, 1.5‐2.5 microg*mL(‐1) propofol)
Number of subjects: 24
Study 11698326 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (2.0 MAC, 4.0 %)
Number of subjects: 24
Study 9150314 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-cultures with autologous alveolar macrophages (AMs) from patients with IPF
Number of subjects: 6
Study 9150314 — intervention group
Group type: COMPARATOR
Intervention: Co-cultures with autologous AMs from normal volunteers (5 nonsmokers and 4 smokers)
Number of subjects: 6
Study 9150314 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 treatment in co-cultures with AMs from healthy volunteers
Number of subjects: 6
Study 9150314 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 treatment in co-cultures with AMs from patients with IPF
Number of subjects: 6
Study 9150314 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of CD80 and CD86 on AMs from patients with IPF and normal volunteers
Number of subjects: 6
Study 7950123 — intervention group
Group type: EXPERIMENTAL
Intervention: Transscleral suture fixation of the posterior chamber lens
Number of subjects: 34
Study 7950123 — intervention group
Group type: COMPARATOR
Intervention: Control group (uncomplicated cataract extraction)
Number of subjects: 34
Study 3296136 — intervention group
Group type: EXPERIMENTAL
Intervention: levamisole
Number of subjects: 50
Study 29697799 — intervention group
Group type: EXPERIMENTAL
Intervention: 2014
Number of subjects: 53439
Study 29697799 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 53439
Study 29697799 — intervention group
Group type: EXPERIMENTAL
Intervention: More educated individuals
Number of subjects: 53439
Study 29697799 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 53439
Study 29697799 — intervention group
Group type: EXPERIMENTAL
Intervention: Country size
Number of subjects: 53439
Study 29697799 — intervention group
Group type: EXPERIMENTAL
Intervention: 2014 willingness to travel
Number of subjects: 53439
Study 28455085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen 1000 mg every 8 hours for 48 hours (total of 6 doses)
Number of subjects: 104
Study 28455085 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mL saline) every 8 hours for 48 hours (total of 6 doses)
Number of subjects: 104
Study 28455085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 104
Study 28455085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 26790216 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electric stimulation (group A)
Number of subjects: 90
Study 26790216 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupoint (group B)
Number of subjects: 90
Study 26790216 — intervention group
Group type: COMPARATOR
Intervention: Blank control (group C)
Number of subjects: 90
Study 23782729 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate therapeutic hypothermia (33°C ± 1) over at least 72 hours in addition to early decompressive hemicraniectomy
Number of subjects: 0
Study 23782729 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional outcome assessment at day 14 and at 12 months follow-up
Number of subjects: 0
Study 23782729 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications related to hypothermia
Number of subjects: 0
Study 21164304 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedation (IVS)
Number of subjects: 63
Study 21164304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine (IAL)
Number of subjects: 63
Study 18234557 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM-BpTRU system
Number of subjects: 17
Study 18234557 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM-Spacelabs system
Number of subjects: 17
Study 18234557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 17
Study 17024938 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐Bond + Filtek‐Flow + Filtek Z250
Number of subjects: 19
Study 17024938 — intervention group
Group type: COMPARATOR
Intervention: Single‐Bond + Filtek Z250
Number of subjects: 19
Study 12777347 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants reporting general trauma (n=38)
Number of subjects: 96
Study 12777347 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants reporting childhood sexual abuse (n=15)
Number of subjects: 96
Study 10551154 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling with adjunctive antimicrobial therapy
Number of subjects: 34
Study 10551154 — intervention group
Group type: COMPARATOR
Intervention: Full mouth scaling alone
Number of subjects: 34
Study 8752776 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of 20 micrograms.h-1 of buprenorphine (Bu) with additional 20 micrograms of Bu
Number of subjects: 21
Study 8752776 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of 20 micrograms.h-1 of Bu plus 1 mg.h-1 of bupivacaine (Bup) with additional 20 micrograms of Bu plus 1 mg of Bup
Number of subjects: 21
Study 8752776 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of 20 micrograms.h-1 of Bu plus 2 mg.h-1 of Bup with additional 20 micrograms of Bu plus 2 mg of Bup
Number of subjects: 21
Study 8752776 — intervention group
Group type: COMPARATOR
Intervention: Self controlled analgesia system (control group)
Number of subjects: 21
Study 1899206 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control of blood pressure
Number of subjects: 74
Study 1899206 — intervention group
Group type: COMPARATOR
Intervention: Manual control of blood pressure
Number of subjects: 74
Study 6312942 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hemodialysis
Number of subjects: 8
Study 6312942 — intervention group
Group type: COMPARATOR
Intervention: Sham hemodialysis
Number of subjects: 8
Study 29510791 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep education website (Sleep to Stay Awake); intervention duration: 8 weeks; participants completed surveys at baseline, 1 week, and 8 weeks.
Number of subjects: 549
Study 29510791 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep education website (Sleep to Stay Awake); intervention duration: 8 weeks.
Number of subjects: 549
Study 26747051 — intervention group
Group type: EXPERIMENTAL
Intervention: APOL1 genetic testing at baseline
Number of subjects: 0
Study 26747051 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (APOL1 genetic testing at one year)
Number of subjects: 0
Study 25329552 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Start
Number of subjects: 3790
Study 25329552 — intervention group
Group type: COMPARATOR
Intervention: Other center-based care
Number of subjects: 3790
Study 23192781 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoxetate disodium (10 mL, n = 97; 8 mL, n = 1; 16 mL, n = 1)
Number of subjects: 192
Study 23192781 — intervention group
Group type: COMPARATOR
Intervention: Gadobenate dimeglumine (0.1 mmol per kilogram of body weight, maximum dose, 20 mL)
Number of subjects: 192
Study 21126389 — intervention group
Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride (1 mg, im, q. 12 h)
Number of subjects: 45
Study 21126389 — intervention group
Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride
Number of subjects: 45
Study 21126389 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 45
Study 21126389 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 18503218 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (10 mg/kg orally, 3 times per week for 12 months)
Number of subjects: 20
Study 18503218 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 20
Study 18503218 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Number of subjects: 20
Study 18503218 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation and untreated control group
Number of subjects: 20
Study 15904591 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral rectus sheath block (BRSB) with 25 mg of bupivacaine
Number of subjects: 91
Study 15904591 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal (IP) instillation of 25 mg of bupivacaine
Number of subjects: 91
Study 15904591 — intervention group
Group type: COMPARATOR
Intervention: Intraincisional (II) instillation of 25 mg of bupivacaine
Number of subjects: 91
Study 12580839 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100-150 mg/day for five days starting from day 2 of the cycle and 150 IU of hMG/day on days 6-10, GnRH antagonist (Centrorelix) 0.25 mg/day started when the leading follicle reached 16 mm in the absence of an LH surge
Number of subjects: 189
Study 12580839 — intervention group
Group type: COMPARATOR
Intervention: Long-acting GnRH agonist (Deacapeptyl) 0.1 mg/day as standard long protocol
Number of subjects: 189
Study 10459624 — intervention group
Group type: COMPARATOR
Intervention: 3 MU of interferon alpha-2b, three times a week for 6 months (Group A)
Number of subjects: 62
Study 10459624 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU of interferon alpha-2b plus 600 mg/day of ribavirin for 6 months (Group B)
Number of subjects: 62
Study 10459624 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 62
Study 10459624 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (ribavirin)
Number of subjects: 62